COLL · Company research
Collegium Pharmaceutical, Inc. Common Stock (COLL): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
21records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| COLL vs. DSNKY: Which Stock Is the Better Value Option? | In a comparison of two medical-drugs stocks, Collegium Pharmaceutical (COLL) emerges as the better value investment option compared to Daiichi Sankyo (DSNKY). COLL holds a Zacks Rank of #1 (Strong Buy) with a Value grade of A, featuring a forward P/E of 3.14 and PEG ratio of 0.63. DSNKY has a Zacks Rank of #5 (Strong Sell) with a Value grade of C, showing a forward P/E of 18.47 and PEG ratio of 1.83. | View source ↗ | Zacks Investment Research | Oct 19, 2026 | neutral | 0 | 1 |
| Does Collegium Pharmaceutical (COLL) Have the Potential to Rally 111.39% as Wall Street Analysts Expect? | Collegium Pharmaceutical (COLL) closed at $23.18 with a mean analyst price target of $49, suggesting 111.4% upside potential. The stock has a Zacks Rank #1 (Strong Buy) rating and shows positive earnings estimate revisions, with the consensus estimate for the current year increasing 3.8% over the last 30 days. However, the article cautions that price targets alone should not be the sole basis for investment decisions. | View source ↗ | Zacks Investment Research | Oct 16, 2026 | bullish | 1 | 1 |
| Does Collegium Pharmaceutical (COLL) Have the Potential to Rally 111.39% as Wall Street Analysts Expect? | Collegium Pharmaceutical (COLL) closed at $23.18 with a mean analyst price target of $49, suggesting 111.4% upside potential. The stock has a Zacks Rank #1 (Strong Buy) rating and shows positive earnings estimate revisions, with the consensus estimate for the current year increasing 3.8% over the last 30 days. However, the article cautions that price targets alone should not be the sole basis for investment decisions. | View source ↗ | Zacks Investment Research | Oct 16, 2026 | bullish | 1 | 1 |
| Collegium Pharmaceutical, Inc. (COLL) Stock Forecasts - Yahoo! Finance Canada | Collegium Pharmaceutical, Inc. (COLL) Stock Forecasts Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 15, 2026 | neutral | 0 | 0.6 |
| Collegium Pharmaceutical, Inc. (COLL) Stock Forecasts - Yahoo Finance | Collegium Pharmaceutical, Inc. (COLL) Stock Forecasts Yahoo Finance | View source ↗ | Yahoo Finance | Oct 14, 2026 | neutral | 0 | 0.6 |
| Behavioral Patterns of COLL and Institutional Flows - Stock Traders Daily | Behavioral Patterns of COLL and Institutional Flows Stock Traders Daily | View source ↗ | Stock Traders Daily | Oct 11, 2026 | neutral | 0 | 0.6 |
| Collegium Pharmaceutical, Inc. (COLL) Stock forecasts - Yahoo Finance UK | Collegium Pharmaceutical, Inc. (COLL) Stock forecasts Yahoo Finance UK | View source ↗ | Yahoo Finance UK | Oct 9, 2026 | neutral | 0 | 0.6 |
| Four investors report shared voting power over Collegium Pharma (COLL) shares. - Stock Titan | Four investors report shared voting power over Collegium Pharma (COLL) shares. Stock Titan | View source ↗ | Stock Titan | Oct 8, 2026 | neutral | 0 | 0.6 |
| Collegium Pharmaceutical, Inc. (COLL) Stock Forecasts - Yahoo Finance | Collegium Pharmaceutical, Inc. (COLL) Stock Forecasts Yahoo Finance | View source ↗ | Yahoo Finance | Oct 8, 2026 | neutral | 0 | 0.6 |
| Collegium Pharmaceutical, Inc. (COLL) Stock Price, News, Quote & History - Yahoo! Finance Canada | Collegium Pharmaceutical, Inc. (COLL) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 8, 2026 | neutral | 0 | 0.6 |
| Collegium Pharmaceutical, Inc. (COLL) Stock Forecasts - Yahoo! Finance Canada | Collegium Pharmaceutical, Inc. (COLL) Stock Forecasts Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 8, 2026 | neutral | 0 | 0.6 |
| New Strong Sell Stocks for October 7th | Zacks has added three stocks to its Strong Sell list today: Ardelyx (ARDX), a biopharmaceutical company with a 53.9% downward earnings revision; Southwest Airlines (LUV), a passenger airline with a 4.1% downward earnings revision; and Collegium Pharmaceutical (COLL), a specialty pharmaceutical company with a nearly 3% downward earnings revision over the last 60 days. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | bearish | -1 | 1 |
| New Strong Sell Stocks for October 7th | Zacks has added three stocks to its Strong Sell list today: Ardelyx (ARDX), a biopharmaceutical company with a 53.9% downward earnings revision; Southwest Airlines (LUV), a passenger airline with a 4.1% downward earnings revision; and Collegium Pharmaceutical (COLL), a specialty pharmaceutical company with a nearly 3% downward earnings revision over the last 60 days. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | bearish | -1 | 1 |
| An estimated 15.5 million U.S. adults have ADHD. Three guides help families navigate care and school. - Stock Titan | An estimated 15.5 million U.S. adults have ADHD. Three guides help families navigate care and school. Stock Titan | View source ↗ | Stock Titan | Oct 6, 2026 | neutral | 0 | 0.6 |
| Former officer Scott Dreyer proposes selling 27,419 Collegium Pharmaceutical (COLL) shares. - Stock Titan | Former officer Scott Dreyer proposes selling 27,419 Collegium Pharmaceutical (COLL) shares. Stock Titan | View source ↗ | Stock Titan | Sep 30, 2026 | neutral | 0 | 0.6 |
| Collegium Pharmaceutical (COLL) Stock Revenue Growth Masks Deepening Margin Squeeze - Simply Wall Street | Collegium Pharmaceutical (COLL) Stock Revenue Growth Masks Deepening Margin Squeeze Simply Wall Street | View source ↗ | Simply Wall Street | Aug 8, 2026 | neutral | 0 | 0.6 |
| Collegium Pharmaceutical (COLL) Stock May Trade At A Discount Even After A 60% Return - Simply Wall Street | Collegium Pharmaceutical (COLL) Stock May Trade At A Discount Even After A 60% Return Simply Wall Street | View source ↗ | Simply Wall Street | Aug 7, 2026 | neutral | 0 | 0.6 |
| COLL Q2 Deep Dive: ADHD Expansion and Pain Business Headwinds Shape Guidance - StockStory | COLL Q2 Deep Dive: ADHD Expansion and Pain Business Headwinds Shape Guidance StockStory | View source ↗ | StockStory | Aug 6, 2026 | neutral | 0 | 0.6 |
| Collegium Pharmaceutical (NASDAQ:COLL) Reports Sales Below Analyst Estimates In Q2 CY2026 Earnings, Stock Drops - StockStory | Collegium Pharmaceutical (NASDAQ:COLL) Reports Sales Below Analyst Estimates In Q2 CY2026 Earnings, Stock Drops StockStory | View source ↗ | StockStory | Aug 6, 2026 | neutral | 0 | 0.6 |
| Collegium Pharmaceutical (COLL) Reports Earnings Tomorrow: What To Expect - StockStory | Collegium Pharmaceutical (COLL) Reports Earnings Tomorrow: What To Expect StockStory | View source ↗ | StockStory | Aug 5, 2026 | neutral | 0 | 0.6 |
| Why Collegium Pharmaceutical Inc. (COLL) Stock Is Gaining Attention for Its ADHD Portfolio - Yahoo Finance | Why Collegium Pharmaceutical Inc. (COLL) Stock Is Gaining Attention for Its ADHD Portfolio Yahoo Finance | View source ↗ | Yahoo Finance | May 27, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.